Search company, investor...
Genegoggle company logo



Seed | Alive

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About Genegoggle

Genegoggle is a Polish firm using multidimensional genomic and epigenetic elements for drug discovery.

Headquarters Location

al. Jana Pawła II 22

Warsaw, 00-133,


Missing: Genegoggle's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Genegoggle's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Genegoggle News

09:07 ET Genegoggle announces milestone on characterising the 3D genome of paediatric brain cancer cells

Feb 23, 2022

Unmet need in diagnosis and treatment of fatal diffuse intrinsic pontine glioma Novel DNA-DNA contacts due to K27M mutation in gene H3F3A characterise DIPG News provided by Share this article Share this article WARSAW, Poland, Feb. 23, 2022 /CNW/ -- Genegoggle is unveiling the chromatin physical properties (3D DNA folding) of cells derived from diffuse intrinsic pontine gliomas (DIPG). The current work is oriented to finding DNA-DNA contacts that can be used as cell type markers to characterise DIPG cells and as drug delivery targets. Michał Marzęcki, Chief Technical Officer, declared that "this is another crucial milestone confirming the rightness of our solution and increasing our value proposition". Genegoggle Epigenetic Viewer shows changes in DNA loops between cancer and control cells One of the hallmarks of DIPG is a mutation in histone H3.3 that leads to the change of the amino acid lysine to methionine (K27M), which influences epigenetic processes. Genegoggle has successfully identified dozens of DNA-DNA contacts (aka DNA loops) exclusive to DIPG cells carrying the K27M mutation and changes in the H3K27me3 profile when compared with normal cells. By using cutting-edge epigenetic technology, many of these DNA loops have been linked to differential gene expression and differential chromatin accessibility. "These results inform us about several histone modification profiles to describe chromatin states of DIPG cells better, that will allow us to identify novel characteristics and clinical targets," said Jakub Mieczkowski, PhD, and Chief Executive Officer. The data was obtained during the Illumina Accelerator partnership and in collaboration with Prof. Jacek Majewski from McGill University. When asked about Genegoggle's future, Chief Business Officer Marcin Kruczyk, PhD, said, "we believe that we are strongly positioned for the next round of fundraising to take this journey forward". About diffuse intrinsic pontine glioma (DIPG) Diffuse intrinsic pontine glioma is the most common type of paediatric brain-stem cancer. The median survival for children with DIPG is less than one year from diagnosis, and little improvement in survival has been achieved in decades. The current diagnostic method is MRI examination (magnetic resonance imaging) and usually takes place when the symptoms are advanced. A genetic hallmark of DIPG is a mutation in the gene H3F3A that encodes histone H3.3. About Genegoggle Genegoggle is an innovative biotech company that offers platform centric solutions to the challenges of precision medicine and contributes to the realisation of the future of health. Through its disruptive approach and AI-powered tools for designing next-generation compounds, Genegoggle aims at developing selective delivery systems that target specific types of cells. Based on the data provided by its Genegoggle Epigenetic Viewer software, Genegoggle is systematically analysing the 3D structure of DNA, identifying epigenetic modifications and mutations, comparing healthy and pathological cells, measuring parameters between genomic regions of interest, and understanding the current state of the chromatin. This technology is a prelude to novel epigenetics-based applications such as identification of genome-editing targets, inspection of DNA damage for space travelling purposes, selective drug activation, and many others. For more information, visit and follow us on LinkedIn and Twitter ( @genegoggle ).

Genegoggle Frequently Asked Questions (FAQ)

  • Where is Genegoggle's headquarters?

    Genegoggle's headquarters is located at al. Jana Pawła II 22, Warsaw.

  • What is Genegoggle's latest funding round?

    Genegoggle's latest funding round is Seed.

  • Who are the investors of Genegoggle?

    Investors of Genegoggle include Illumina Accelerator.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.